• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Large owner Ecor1 Capital, Llc sold $50,839,807 worth of Ordinary Shares (6,279,684 units at $8.10) (SEC Form 4)

    5/6/25 7:06:05 PM ET
    $PRTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRTA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    EcoR1 Capital, LLC

    (Last) (First) (Middle)
    357 TEHAMA STREET #3

    (Street)
    SAN FRANCISCO CA 94103

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    PROTHENA CORP PUBLIC LTD CO [ PRTA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/02/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Ordinary Shares 05/02/2025 S 3,317,938(2) D $8.3621(3) 8,266,342(4) I See Note(1)
    Ordinary Shares 05/05/2025 S 977,693(5) D $8.1111(6) 7,288,649(7) I See Note(1)
    Ordinary Shares 05/06/2025 S 1,984,053(8) D $7.6433(9) 5,304,596(10) I See Note(1)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Fund"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.
    2. Qualified Fund sold 3,097,619 of the shares sold in this transaction.
    3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.2715 to $9.1789, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each seperate price within the ranges set forth in this footnote and footnotes 6 and 9.
    4. After this transaction, Qualified Fund held 7,750,234 shares of the Issuer's Common Stock.
    5. Qualified Fund sold 916,492 of the shares of sold in this transaction.
    6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.1097 to $8.1972, inclusive.
    7. After this transaction, Qualified Fund held 6,833,742 shares of the Issuer's Common Stock
    8. Qualified Fund sold 1,859,851 of the shares sold in this transaction.
    9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.4637 to $8.5939, inclusive.
    10. After this transaction, Qualified Fund held 4,973,891 of the Issuer's Ordinary Shares.
    /s/ Oleg Nodelman 05/06/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PRTA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRTA

    DatePrice TargetRatingAnalyst
    12/20/2024$40.00Buy
    Chardan Capital Markets
    1/30/2024$68.00 → $38.00Buy → Neutral
    BofA Securities
    12/12/2023$62.00Buy
    Deutsche Bank
    4/24/2023$80.00Outperform
    SVB Securities
    1/27/2023$94.00Overweight
    Piper Sandler
    11/4/2022$52.00 → $55.00Outperform → Sector Perform
    RBC Capital Mkts
    9/28/2022Neutral → Buy
    BofA Securities
    11/19/2021$77.00Market Outperform
    JMP Securities
    More analyst ratings

    $PRTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Prothena Reports First Quarter 2025 Financial Results and Business Highlights

      Net cash used in operating and investing activities was $53.4 million in the first quarter of 2025; quarter-end cash and restricted cash position was $418.8 million Topline results expected in 2Q 2025 from the confirmatory Phase 3 AFFIRM-AL clinical trial of birtamimab in patients with Mayo Stage IV AL amyloidosis being conducted under a SPA agreement with the FDA with a primary endpoint of all-cause mortality (time-to-event) at a statistical significance level of 0.10 Multiple clinical readouts for PRX012, a potential single-injection once-monthly subcutaneous treatment for millions of patients with presymptomatic or early symptomatic Alzheimer's disease, expected starting around mid-

      5/8/25 4:05:00 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prothena to Report First Quarter 2025 Financial Results on May 8

      Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on May 8. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of deva

      5/1/25 4:05:00 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

      Net cash used in operating and investing activities was $47.8 million in the fourth quarter and $150.3 million for the full year of 2024; quarter-end cash and restricted cash position was $472.2 million The company expects cash guidance for the full year 2025 net cash used in operating and investing activities to be $168 to $175 million and expects to end the year with approximately $301 million in cash (midpoint) Topline results expected in 2Q 2025 from the confirmatory Phase 3 AFFIRM-AL clinical trial of birtamimab in patients with Mayo Stage IV AL amyloidosis being conducted under a SPA agreement with the FDA with a primary endpoint of all-cause mortality (time-to-event) at a statis

      2/20/25 4:05:00 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTA
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Prothena Corporation plc

      SCHEDULE 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)

      5/14/25 10:34:49 AM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Prothena Corporation plc

      10-Q - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)

      5/8/25 4:15:12 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prothena Corporation plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)

      5/8/25 4:10:38 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Ecor1 Capital, Llc sold $50,839,807 worth of Ordinary Shares (6,279,684 units at $8.10) (SEC Form 4)

      4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)

      5/6/25 7:06:05 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Scully William P received a gift of 430,000 units of Ordinary Shares, bought $2,749,916 worth of Ordinary Shares (207,436 units at $13.26) and gifted 747,700 units of Ordinary Shares, decreasing direct ownership by 7% to 735,993 units (SEC Form 4)

      4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)

      5/2/25 10:29:05 AM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Scully William P claimed ownership of 1,037,207 units of Ordinary Shares (SEC Form 3)

      3 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)

      5/1/25 9:19:59 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTA
    Leadership Updates

    Live Leadership Updates

    See more
    • Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

      Net cash used in operating and investing activities was $45.2 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-end cash and restricted cash position was $520.1 million PRX012, a potential single-injection once-monthly subcutaneous treatment, is designed to address the unmet need of millions of patients with presymptomatic or early symptomatic Alzheimer's disease; Prothena expects to report multiple clinical readouts starting in mid-2025 and continuing throughout the year from the ongoing Phase 1 ASCENT clinical trials Results from partner Roche evaluating prasinezumab in patients with early Parkinson's disease from the Phase 2 PASA

      11/12/24 4:05:00 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prothena Reports First Quarter 2024 Financial Results and Business Highlights

      Net cash used in operating and investing activities was $73.2 million in the first quarter of 2024; quarter-end cash and restricted cash position was $548.7 million Advanced potential best-in-class Alzheimer's disease portfolio: initial data supportive of ongoing Phase 1 clinical trial for PRX012, an anti-amyloid beta antibody; received FDA clearance for IND application and Fast Track designation for PRX123, a dual amyloid beta/tau vaccine; Phase 2 clinical trial initiated in patients with early Alzheimer's disease for BMS-986446 (formerly PRX005) by partner Bristol Myers Squibb Strengthened leadership position in the amyloidosis community with ongoing enrollment of the confirmatory

      5/8/24 4:05:00 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prothena Appoints David Ford to Newly Created Chief People Officer Position

      Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it has named David Ford to a newly created position of Chief People Officer, reporting to Prothena President and Chief Executive Officer Gene Kinney, PhD. In this role, Mr. Ford will be responsible for people, culture, and human resources strategy to drive the company's vision and overall growth strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240304692974/en/David Ford, Chief People Officer, Prothena (Photo: Business Wire

      3/4/24 4:05:00 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on Prothena with a new price target

      Chardan Capital Markets initiated coverage of Prothena with a rating of Buy and set a new price target of $40.00

      12/20/24 7:48:38 AM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prothena downgraded by BofA Securities with a new price target

      BofA Securities downgraded Prothena from Buy to Neutral and set a new price target of $38.00 from $68.00 previously

      1/30/24 7:38:21 AM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deutsche Bank initiated coverage on Prothena with a new price target

      Deutsche Bank initiated coverage of Prothena with a rating of Buy and set a new price target of $62.00

      12/12/23 8:06:31 AM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Prothena Corporation plc

      SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)

      11/14/24 1:22:34 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Prothena Corporation plc

      SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)

      11/13/24 7:00:50 AM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Prothena Corporation plc

      SC 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)

      11/13/24 6:06:27 AM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Scully William P received a gift of 430,000 units of Ordinary Shares, bought $2,749,916 worth of Ordinary Shares (207,436 units at $13.26) and gifted 747,700 units of Ordinary Shares, decreasing direct ownership by 7% to 735,993 units (SEC Form 4)

      4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)

      5/2/25 10:29:05 AM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTA
    Financials

    Live finance-specific insights

    See more
    • Prothena to Report First Quarter 2025 Financial Results on May 8

      Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on May 8. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of deva

      5/1/25 4:05:00 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

      Net cash used in operating and investing activities was $47.8 million in the fourth quarter and $150.3 million for the full year of 2024; quarter-end cash and restricted cash position was $472.2 million The company expects cash guidance for the full year 2025 net cash used in operating and investing activities to be $168 to $175 million and expects to end the year with approximately $301 million in cash (midpoint) Topline results expected in 2Q 2025 from the confirmatory Phase 3 AFFIRM-AL clinical trial of birtamimab in patients with Mayo Stage IV AL amyloidosis being conducted under a SPA agreement with the FDA with a primary endpoint of all-cause mortality (time-to-event) at a statis

      2/20/25 4:05:00 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

      Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the close of the U.S. financial markets. The announcement will be followed by a live audio conference call at 4:30 PM ET. The conference call will be made available on the Company's website at www.prothena.com under the Investors tab in the Events and Presentations section. Following the live audio webcast, a replay will be available on the Company's website for at least 90 days. T

      2/13/25 4:05:00 PM ET
      $PRTA
      Biotechnology: Pharmaceutical Preparations
      Health Care